Houston, United States
Delphi Diagnostics Inc. is a Texas-based startup focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. The company is known for its innovative and unique tests to guide therapy decisions for breast cancer patients.
Founded in 2016, Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index (EAI), a technology developed by the laboratory of Dr. W. Fraser Symmans. The EAI test measures endocrine activity in stage II-III, HR+HER2- breast cancer, aiming to open new pathways for personalized breast cancer treatment.
The latest investment in Delphi Diagnostics Inc. came from DigitalDx Ventures in a Venture Round investment at 01 January 2019. Operating in the Health Care industry, the company is determined to make the EAI test available to breast cancer patients, potentially revolutionizing how personalized breast cancer treatment is approached.
